MX9800145A - Vectores y virales de tejido especifico. - Google Patents

Vectores y virales de tejido especifico.

Info

Publication number
MX9800145A
MX9800145A MX9800145A MX9800145A MX9800145A MX 9800145 A MX9800145 A MX 9800145A MX 9800145 A MX9800145 A MX 9800145A MX 9800145 A MX9800145 A MX 9800145A MX 9800145 A MX9800145 A MX 9800145A
Authority
MX
Mexico
Prior art keywords
viral vectors
tissue specific
specific viral
specific
adenovirus
Prior art date
Application number
MX9800145A
Other languages
English (en)
Inventor
Daniel R Henderson
Eric R Schuur
Original Assignee
Calydon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23966983&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9800145(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Calydon Inc filed Critical Calydon Inc
Publication of MX9800145A publication Critical patent/MX9800145A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan vehículos de adenovirus específicos para la célula del huésped para transfectar las células huésped de blanco u objetivo. Proporcionando la regulacion de la iniciacion transcripcional dependiendo de los factores de transcripcion que solo son activos en los tipos de células limitados, específicos, la replicacion del virus estará restringida a las células de blanco u objetivo. El adenovirus modificado puede ser utilizado u objetivo. El adenovirus modificado puede ser utilizado como un vehículo para introducir nuevas capacidades genéticas, asociadas particularmente con la citotoxicidad para tratar la neoplasia.
MX9800145A 1995-06-27 1998-01-07 Vectores y virales de tejido especifico. MX9800145A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/495,034 US5698443A (en) 1995-06-27 1995-06-27 Tissue specific viral vectors

Publications (1)

Publication Number Publication Date
MX9800145A true MX9800145A (es) 1998-11-30

Family

ID=23966983

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9800145A MX9800145A (es) 1995-06-27 1998-01-07 Vectores y virales de tejido especifico.

Country Status (10)

Country Link
US (2) US5698443A (es)
EP (1) EP0844888B1 (es)
JP (1) JP4117347B2 (es)
AT (1) ATE295739T1 (es)
AU (1) AU729648B2 (es)
CA (1) CA2222457A1 (es)
DE (1) DE69634752T2 (es)
ES (1) ES2242196T3 (es)
MX (1) MX9800145A (es)
WO (1) WO1997001358A1 (es)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057299A (en) * 1994-01-13 2000-05-02 Calydon, Inc. Tissue-specific enhancer active in prostate
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) * 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
DK0833934T4 (da) 1995-06-15 2012-11-19 Crucell Holland Bv Pakningssystemer til human rekombinant adenovirus til anvendelse ved genterapi
FR2735789B1 (fr) * 1995-06-23 1997-07-25 Centre Nat Rech Scient Adenovirus recombinants, leur utilisation pour preparer des aav, lignee cellulaire complementaire et compositions pharmaceutiques les contenant
US20020068049A1 (en) * 1998-09-10 2002-06-06 Henderson Daniel R. Tissue specific adenoviral vectors
US6197293B1 (en) * 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US7011976B1 (en) 1997-03-03 2006-03-14 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US6676935B2 (en) * 1995-06-27 2004-01-13 Cell Genesys, Inc. Tissue specific adenoviral vectors
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US7001764B2 (en) * 1995-06-27 2006-02-21 Cell Genesys, Inc. Compositions comprising tissue specific adenoviral vectors
CA2250183A1 (en) * 1996-03-27 1997-10-02 Arie S. Belldegrun Psa positive regulating (psar) sequences and uses thereof
AUPO023496A0 (en) * 1996-05-31 1996-06-27 Commonwealth Scientific And Industrial Research Organisation Modified small RNA viruses
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US5772993A (en) * 1997-01-21 1998-06-30 The University Of Virginia Patent Foundation Osteocalcin promoter-based toxic gene therapy for the treatment of calcified tumors and tissues
US6403370B1 (en) * 1997-02-10 2002-06-11 Genstar Therapeutics Corporation Oncolytic/immunogenic complementary-adenoviral vector system
US6100444A (en) * 1997-02-11 2000-08-08 University Of Rochester Medical Center Prostate specific regulatory nucleic acid sequences and transgenic non-human animals expressing prostate specific antigen
CA2283231C (en) * 1997-03-03 2008-05-20 Calydon, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
JP2002514075A (ja) * 1997-03-03 2002-05-14 セル ジェネシス，インコーポレイティド 癌胎児性抗原を発現する細胞に特異的なアデノウイルスベクターおよびその使用方法
EP1905837A1 (en) * 1997-03-03 2008-04-02 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
US6432700B1 (en) * 1997-03-03 2002-08-13 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
IL120485A0 (en) * 1997-03-19 1997-07-13 Yeda Res & Dev Modulators of the function of receptors of the TNF/NGF receptor family and other proteins
CA2294649C (en) * 1997-06-23 2007-09-25 University Of Saskatchewan Bovine adenovirus type 3 genome
DE69838584T2 (de) 1997-08-04 2008-06-26 Cell Genesys, Inc., Foster City Enhancer des menschlichen glandulären kallikreingens, vektoren die ihn enthalten und methoden für seine verwendung
US6706693B1 (en) 1997-08-13 2004-03-16 The Uab Research Foundation Vaccination by topical application of genetic vectors
US20030045492A1 (en) * 1997-08-13 2003-03-06 Tang De-Chu C. Vaccination by topical application of recombinant vectors
US6716823B1 (en) 1997-08-13 2004-04-06 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom, and uses thereof
US20030125278A1 (en) * 1997-08-13 2003-07-03 Tang De-Chu C. Immunization of animals by topical applications of a salmonella-based vector
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
AU752926B2 (en) * 1997-09-19 2002-10-03 Johnson & Johnson Research Pty. Limited Transgenic autologous T-cell therapy in humans, and related compositions and kits
US7378244B2 (en) * 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
US7780962B2 (en) * 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US7470426B1 (en) * 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US20030044384A1 (en) * 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
AU3311699A (en) * 1998-02-25 1999-09-15 Board Of Regents Of The University And Community College System Of Nevada, The Manganese superoxide dismutase exon 3-deleted isoforms and nucleic acid molecules encoding the isoforms
JP2002520069A (ja) * 1998-07-14 2002-07-09 メルク・アンド・カンパニー・インコーポレーテッド アデノウイルスに基づくプロモーターアッセイ
US6900049B2 (en) * 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US7691370B2 (en) * 1998-10-15 2010-04-06 Canji, Inc. Selectivity replicating viral vector
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6495130B1 (en) 1998-12-30 2002-12-17 Calydon, Inc. Target cell-specific adenoviral vectors containing E3 and methods of use thereof
US20060024273A1 (en) * 1998-12-30 2006-02-02 Henderson Daniel R Target cell-specific adenoviral vectors containing E3 and methods of use thereof
AU4246900A (en) * 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
US20040009936A1 (en) * 1999-05-03 2004-01-15 Tang De-Chu C. Vaccine and drug delivery by topical application of vectors and vector extracts
US6913922B1 (en) * 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US8063022B1 (en) 1999-06-08 2011-11-22 The Children's Hospital Of Philadelphia Methods for preventing formation of inhibitory antibodies in the setting of gene therapy
DE19928342A1 (de) * 1999-06-21 2000-12-28 Deutsches Krebsforsch Vektoren zur gentherapeutischen Tumorbehandlung
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
WO2001027256A2 (en) 1999-10-14 2001-04-19 The Regents Of The University Of California System Chimeric transcriptional regulatory element and methods for prostate-targeted gene expression
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
US20030212022A1 (en) * 2001-03-23 2003-11-13 Jean-Marie Vogel Compositions and methods for gene therapy
US7048920B2 (en) * 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
DE60137208D1 (de) 2000-03-24 2009-02-12 Cell Genesys Inc Menschliche zellspezifische urotheliale regulatorische sequenzen der transkription des uroplakins, dessen vektoren und verwendungsverfahren
US6911200B2 (en) * 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
ES2254042T3 (es) 2000-03-24 2008-03-16 Biosphere Medical, Inc. Microesferas para embolizacion activa.
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗－cd20在b细胞淋巴瘤治疗中的联合应用
US20040101825A1 (en) * 2001-09-26 2004-05-27 Van Meir Erwin G. Viruses targeted to hypoxic cells and tissues
US7285414B2 (en) * 2000-09-26 2007-10-23 Emory University Viruses targeted to hypoxic cells and tissues
EP1207205A1 (en) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenoviral replicons
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
ES2287181T3 (es) * 2000-12-28 2007-12-16 Per Sonne Holm Sistemas adenovirales y sus aplicaciones.
CA2432991A1 (en) * 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
EP1377672A2 (en) * 2001-02-23 2004-01-07 Novartis AG Vector constructs
US20030021768A1 (en) * 2001-07-23 2003-01-30 Yuqiao Shen Viral mutants that selectively replicate in targeted human cancer cells
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
EP1453536A4 (en) 2001-12-12 2009-08-26 Mayne Pharma Int Pty Ltd COMPOSITION FOR PRESERVING VIRUSES
ATE447037T1 (de) * 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
CN1655827B (zh) 2002-05-27 2010-06-23 佩尔·松内·霍尔姆 腺病毒和编码其的核酸的新应用
US7364727B2 (en) * 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US20050095705A1 (en) * 2003-04-15 2005-05-05 Michael Kadan Method for production of oncolytic adenoviruses
EP1636360A4 (en) * 2003-06-03 2006-11-08 Cell Genesys Inc COMPOSITIONS AND METHODS FOR ENHANCED EXPRESSION OF RECOMBINANT POLYPEPTIDES FROM A SINGLE VECTOR USING A PEPTIDE CLEAVAGE SITE
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
US20050079158A1 (en) * 2003-06-05 2005-04-14 Shenzhen Allucks Biotech Co., Ltd. Construct of anti-cancer recombinant adenovirus, method for preparing the same and use thereof
AU2004263274B2 (en) 2003-07-21 2009-11-05 Transgene S.A. Novel multifunctional cytokines
US20050186178A1 (en) * 2003-08-28 2005-08-25 Ennist David L. Oncolytic adenoviral vectors encoding GM-CSF
US7482156B2 (en) * 2003-10-15 2009-01-27 Cell Genesys, Inc. Hepatocellular carcinoma specific promoter and uses thereof
US20070110719A1 (en) 2003-11-14 2007-05-17 Holm Per S Novel use of adenoviruses and nucleic acids that code for said viruses
US7473418B2 (en) 2004-03-25 2009-01-06 Cell Genesys, Inc. Pan cancer oncolytic vectors and methods of use thereof
US20050271622A1 (en) * 2004-06-03 2005-12-08 Shenzhen Allucks Biotech Co., Ltd. Construct of tumor-selective recombinant adenovirus, method for preparing the same and use thereof
GB0416487D0 (en) * 2004-07-23 2004-08-25 Isis Innovation Modified virus
US20090221477A1 (en) * 2004-07-26 2009-09-03 Asterion Limited Linkers
US20060062764A1 (en) * 2004-08-25 2006-03-23 Seshidar-Reddy Police Fiber-modified adenoviral vectors for enhanced transduction of tumor cells
US7524510B2 (en) 2005-02-23 2009-04-28 The Uab Research Foundation Alkyl-glycoside enhanced vaccination
US20060205080A1 (en) * 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
CN101237857A (zh) 2005-05-09 2008-08-06 生物领域医疗公司 使用微球和非离子型造影剂的组合物和方法
PE20081723A1 (es) 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
EP2382474B1 (en) 2009-01-20 2015-03-04 Transgene SA Soluble icam-1 as biomarker for prediction of therapeutic response
EP3293257B1 (en) 2009-03-20 2021-08-11 Mesoblast, Inc. Production of reprogrammed pluripotent cells
WO2010108908A1 (en) 2009-03-24 2010-09-30 Transgene Sa Biomarker for monitoring patients
NZ594896A (en) 2009-04-17 2013-07-26 Transgene Sa Biomarker for monitoring patients
RU2552292C2 (ru) 2009-07-10 2015-06-10 Трансжене Са Биомаркер для отбора пациентов и связанные с ним способы
GB0919773D0 (en) 2009-11-12 2009-12-30 Univ Nottingham Induced pluripotent stem cell
CN101899420A (zh) * 2010-01-16 2010-12-01 韩从辉 一种靶向抗前列腺肿瘤的表达超抗原基因的双调控溶瘤腺病毒的制备方法
JP5952815B2 (ja) 2010-08-04 2016-07-13 シズル バイオテクノロジー リミテッド ガンの診断および処置のための方法および化合物
GB201016852D0 (en) 2010-10-07 2010-11-17 Univ York Cell differentiation
GB201102090D0 (en) 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
GB201102091D0 (en) 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
WO2014066443A1 (en) 2012-10-23 2014-05-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
CN111093715A (zh) 2017-09-18 2020-05-01 儿童医院医疗中心 强绝缘子和其在基因递送中的用途
WO2020264361A1 (en) 2019-06-28 2020-12-30 Massachusetts Institute Of Technology Circular strained zymogen compositions and methods of use
AU2021207901A1 (en) 2020-01-14 2022-09-08 Synthekine, Inc. IL2 orthologs and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9001828A (nl) * 1990-08-15 1992-03-02 Centraal Diergeneeskundig Inst Werkwijze voor het wijzigen van het cel-, weefsel- of gastheertropisme van een microoerganisme; aldus verkregen gerecombineerd microorganisme en toepassing daarvan in de geneeskunde en diergeneeskunde.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
PT797676E (pt) * 1993-10-25 2006-05-31 Canji Inc Vector adenoviral recombinante e metodos de utilizacao
US5830686A (en) * 1994-01-13 1998-11-03 Calydon Tissue-specific enhancer active in prostate
WO1996010838A1 (en) * 1994-09-30 1996-04-11 Matsushita Electric Industrial Co., Ltd. Apparatus and method for bonding tape
US5919652A (en) * 1994-11-09 1999-07-06 The Regents Of The University Of California Nucleic acid molecules comprising the prostate specific antigen (PSA) promoter and uses thereof
CA2206205A1 (en) * 1994-11-28 1996-06-06 Genetic Therapy, Inc. Tissue-specific treatment, diagnostic methods, and compositions using replication-deficient vectors
ES2258265T3 (es) * 1994-11-28 2006-08-16 Cell Genesys Inc. Vectores de replicacion con especificidad tisular.
US20030026789A1 (en) * 1995-05-03 2003-02-06 Richard J. Gregory Gene therapy using replication competent targeted adenoviral vectors
AU5750196A (en) * 1995-05-18 1996-11-29 Genetic Therapy, Inc. Gene therapy of hepatocellular carcinoma through cancer-specific gene expression

Also Published As

Publication number Publication date
US5698443A (en) 1997-12-16
DE69634752T2 (de) 2006-01-12
ATE295739T1 (de) 2005-06-15
AU6393296A (en) 1997-01-30
US5871726A (en) 1999-02-16
ES2242196T3 (es) 2005-11-01
WO1997001358A1 (en) 1997-01-16
EP0844888A1 (en) 1998-06-03
EP0844888B1 (en) 2005-05-18
JPH11508770A (ja) 1999-08-03
JP4117347B2 (ja) 2008-07-16
EP0844888A4 (en) 1999-11-03
DE69634752D1 (de) 2005-06-23
AU729648B2 (en) 2001-02-08
CA2222457A1 (en) 1997-01-16

Similar Documents

Publication Publication Date Title
EP0844888A4 (en) TISSUE-SPECIFIC VIRAL VECTORS
CA2063427A1 (en) Rapid, versatile and simple system for expressing genes in eukaryotic cells
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
MX9603002A (es) Procedimiento para la preparacion de virus asociados a los adenovirus (aav), recombinantes, y usos de los mismos.
AU6149596A (en) Tumor- or cell-specific herpes simplex virus replication
EP0919622A3 (en) Surface expression of enzyme in gene directed prodrug therapy
IL110284A0 (en) Viral vectors and their use in gene therapy
AU7335296A (en) Recombinant sendai virus
EP1180932A4 (en) ADENOVIRUS WITH REINFORCED AND CONDITIONALLY REPLICATED INFECTIVE POWER, AND APPLICATIONS THEREOF
GB2286593B (en) Virus with modified binding moiety specific for the target cells
WO1998037185A3 (en) Vectors for controlled gene expression
ATE419266T1 (de) Promotor mit spezifität für hepatozelluläre karzinome und dessen verwendungen
AU4368299A (en) Self-deleting vectors for cancer therapy
AU7738798A (en) EHV-1 vectors
AU3525095A (en) Deffective recombinant adenoviruses with inactivated iva2 gene
WO2000066731A3 (en) Recombinant laminin 5
AU9269898A (en) Artificial viruses derived from papillomavirus, and their uses, in particular gene therapy
AU1814995A (en) Galanin receptor, nucleic acids, transformed cells and uses thereof
WO2004042025A3 (en) Cell-specific adenovirus vector comprising ebv-specific promoter
ATE226638T1 (de) Retroviraler vektor und dessen verwendung in gentherapie
WO1999012945A3 (en) Hydrophobic glycosylamine derivatives, compositions, and methods for use
WO1998003669A3 (en) Vectors for inhibiting hiv and tumor growth
WO1999027123A3 (en) Modified sv40 viral vectors
WO1998058955A3 (en) Nuclear matrix targeting peptides and uses therefor
Heggtveit The Canada Council Art Bank: national treasure, support to artists or decorating service for governments.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: CELL GENESYS, INC.

FG Grant or registration
MM Annulment or lapse due to non-payment of fees